AKT1 and cancer: This observation is consistent with previous reports (Chermesh et al. 2011; Hitachi et al. 2014; Choi et al. 2019), in which activation of the Akt–mTOR pathway ameliorated cancer‐induced muscle wasting and improved muscle function in preclinical models.